Literature DB >> 22988298

Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II.

S-W Grace Cheng1, Michael A Kuzyk, Annie Moradian, Taka-Aki Ichu, Vicky C-D Chang, Jerry F Tien, Sarah E Vollett, Malachi Griffith, Marco A Marra, Gregg B Morin.   

Abstract

CrkRS (Cdc2-related kinase, Arg/Ser), or cyclin-dependent kinase 12 (CKD12), is a serine/threonine kinase believed to coordinate transcription and RNA splicing. While CDK12/CrkRS complexes were known to phosphorylate the C-terminal domain (CTD) of RNA polymerase II (RNA Pol II), the cyclin regulating this activity was not known. Using immunoprecipitation and mass spectrometry, we identified a 65-kDa isoform of cyclin K (cyclin K1) in endogenous CDK12/CrkRS protein complexes. We show that cyclin K1 complexes isolated from mammalian cells contain CDK12/CrkRS but do not contain CDK9, a presumed partner of cyclin K. Analysis of extensive RNA-Seq data shows that the 65-kDa cyclin K1 isoform is the predominantly expressed form across numerous tissue types. We also demonstrate that CDK12/CrkRS is dependent on cyclin K1 for its kinase activity and that small interfering RNA (siRNA) knockdown of CDK12/CrkRS or cyclin K1 has similar effects on the expression of a luciferase reporter gene. Our data suggest that cyclin K1 is the primary cyclin partner for CDK12/CrkRS and that cyclin K1 is required to activate CDK12/CrkRS to phosphorylate the CTD of RNA Pol II. These properties are consistent with a role of CDK12/CrkRS in regulating gene expression through phosphorylation of RNA Pol II.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22988298      PMCID: PMC3486194          DOI: 10.1128/MCB.06267-11

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  66 in total

1.  Evolution of cyclin-dependent kinases (CDKs) and CDK-activating kinases (CAKs): differential conservation of CAKs in yeast and metazoa.

Authors:  J Liu; E T Kipreos
Journal:  Mol Biol Evol       Date:  2000-07       Impact factor: 16.240

Review 2.  Controlling the elongation phase of transcription with P-TEFb.

Authors:  B Matija Peterlin; David H Price
Journal:  Mol Cell       Date:  2006-08-04       Impact factor: 17.970

Review 3.  Bur1/Bur2 and the Ctk complex in yeast: the split personality of mammalian P-TEFb.

Authors:  Adam Wood; Ali Shilatifard
Journal:  Cell Cycle       Date:  2006-05-15       Impact factor: 4.534

4.  Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription.

Authors:  T J Fu; J Peng; G Lee; D H Price; O Flores
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

Review 5.  Regulatory functions of Cdk9 and of cyclin T1 in HIV tat transactivation pathway gene expression.

Authors:  G Romano; M Kasten; G De Falco; P Micheli; K Khalili; A Giordano
Journal:  J Cell Biochem       Date:  1999-12-01       Impact factor: 4.429

6.  Pkn is a novel partner of cyclin T2a in muscle differentiation.

Authors:  Giuliano Cottone; Alfonso Baldi; Emanuele Palescandolo; Lucrezia Manente; Roberta Penta; Marco G Paggi; Antonio De Luca
Journal:  J Cell Physiol       Date:  2006-04       Impact factor: 6.384

7.  Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription.

Authors:  M Zhou; M A Halanski; M F Radonovich; F Kashanchi; J Peng; D H Price; J N Brady
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

8.  Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation.

Authors:  Hung-Hsi Chen; Yu-Chiuan Wang; Ming-Ji Fann
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

Review 9.  "Cotranscriptionality": the transcription elongation complex as a nexus for nuclear transactions.

Authors:  Roberto Perales; David Bentley
Journal:  Mol Cell       Date:  2009-10-23       Impact factor: 17.970

10.  Modification of the Creator recombination system for proteomics applications--improved expression by addition of splice sites.

Authors:  Karen Colwill; Clark D Wells; Kelly Elder; Marilyn Goudreault; Kadija Hersi; Sarang Kulkarni; W Rod Hardy; Tony Pawson; Gregg B Morin
Journal:  BMC Biotechnol       Date:  2006-03-06       Impact factor: 2.563

View more
  54 in total

1.  Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.

Authors:  Kaiwei Liang; Xin Gao; Joshua M Gilmore; Laurence Florens; Michael P Washburn; Edwin Smith; Ali Shilatifard
Journal:  Mol Cell Biol       Date:  2015-01-05       Impact factor: 4.272

Review 2.  The pol II CTD: new twists in the tail.

Authors:  Justyna Zaborowska; Sylvain Egloff; Shona Murphy
Journal:  Nat Struct Mol Biol       Date:  2016-09-06       Impact factor: 15.369

Review 3.  Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.

Authors:  Arno L Greenleaf
Journal:  Transcription       Date:  2018-10-22

4.  Cyclin-dependent kinase 12 increases 3' end processing of growth factor-induced c-FOS transcripts.

Authors:  Tristan T Eifler; Wei Shao; Koen Bartholomeeusen; Koh Fujinaga; Stefanie Jäger; Jeff R Johnson; Zeping Luo; Nevan J Krogan; B Matija Peterlin
Journal:  Mol Cell Biol       Date:  2014-11-10       Impact factor: 4.272

5.  CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.

Authors:  C Delehouzé; K Godl; N Loaëc; C Bruyère; N Desban; N Oumata; H Galons; T I Roumeliotis; E G Giannopoulou; J Grenet; D Twitchell; J Lahti; N Mouchet; M-D Galibert; S D Garbis; L Meijer
Journal:  Oncogene       Date:  2013-12-09       Impact factor: 9.867

6.  Integrated proteomic analysis of post-translational modifications by serial enrichment.

Authors:  Philipp Mertins; Jana W Qiao; Jinal Patel; Namrata D Udeshi; Karl R Clauser; D R Mani; Michael W Burgess; Michael A Gillette; Jacob D Jaffe; Steven A Carr
Journal:  Nat Methods       Date:  2013-06-09       Impact factor: 28.547

7.  The SNAP25 Interactome in Ventromedial Caudate in Schizophrenia Includes the Mitochondrial Protein ARF1.

Authors:  Alfredo Ramos-Miguel; Vilte Barakauskas; Jehan Alamri; Masatoshi Miyauchi; Alasdair M Barr; Clare L Beasley; Gorazd Rosoklija; J John Mann; Andrew J Dwork; Annie Moradian; Gregg B Morin; William G Honer
Journal:  Neuroscience       Date:  2019-01-02       Impact factor: 3.590

8.  Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.

Authors:  Poorval M Joshi; Shari L Sutor; Catherine J Huntoon; Larry M Karnitz
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

9.  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.

Authors:  Tinghu Zhang; Nicholas Kwiatkowski; Calla M Olson; Sarah E Dixon-Clarke; Brian J Abraham; Ann K Greifenberg; Scott B Ficarro; Jonathan M Elkins; Yanke Liang; Nancy M Hannett; Theresa Manz; Mingfeng Hao; Bartlomiej Bartkowiak; Arno L Greenleaf; Jarrod A Marto; Matthias Geyer; Alex N Bullock; Richard A Young; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2016-08-29       Impact factor: 15.040

Review 10.  CDK inhibitors in cancer therapy, an overview of recent development.

Authors:  Mengna Zhang; Lingxian Zhang; Ruoxuan Hei; Xiao Li; Haonan Cai; Xuan Wu; Qiping Zheng; Cheguo Cai
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.